GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (TSE:4502) » Definitions » Research & Development

Takeda Pharmaceutical Co (TSE:4502) Research & Development : 円729,924 Mil (TTM As of Mar. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Takeda Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Takeda Pharmaceutical Co's Research & Development for the three months ended in Mar. 2024 was 円195,856 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was 円729,924 Mil.

Takeda Pharmaceutical Co Research & Development Historical Data

The historical data trend for Takeda Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Research & Development Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 492,381.00 455,833.00 526,087.00 633,325.00 729,924.00

Takeda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160,944.00 162,741.00 183,946.00 187,381.00 195,856.00

Takeda Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円729,924 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co  (TSE:4502) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Takeda Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (TSE:4502) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (TSE:4502) » Definitions » Research & Development
Comparable Companies
TSE:4523 TSE:4507 TSE:4581 TSE:4516 TSE:4530 TSE:4887 TSE:4540 TSE:4506 TSE:4547 TSE:4521 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA XSWX:SDZ VTRS NBIX SZSE:000538 NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
TAK:USA TKPHF:USA TAK:Mexico TKD:Germany TAKP34:Brazil
Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Website
https://www.takeda.com
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (TSE:4502) Headlines

No Headlines